checkAd

    DGAP-Adhoc  809  0 Kommentare PAION REPORTS POSITIVE HEADLINE DATA IN U.S. CLINICAL SAFETY TRIAL OF REMIMAZOLAM IN HIGH-RISK PATIENTS UNDERGOING COLONOSCOPY - Seite 3




     






    26-March-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de




























    Language: English
    Company: PAION AG
    Martinstr. 10-12
    52062 Aachen
    Germany
    Phone: +49 (0)241-4453-0
    Fax: +49 (0)241-4453-100
    E-mail: info@paion.com
    Internet: www.paion.com
    ISIN: DE000A0B65S3
    WKN: A0B65S
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange





     
    End of Announcement DGAP News Service



    558269  26-March-2017 CET/CEST








    Lesen Sie auch

    Seite 3 von 3



    Diskutieren Sie über die enthaltenen Werte



    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    DGAP-Adhoc PAION REPORTS POSITIVE HEADLINE DATA IN U.S. CLINICAL SAFETY TRIAL OF REMIMAZOLAM IN HIGH-RISK PATIENTS UNDERGOING COLONOSCOPY - Seite 3 DGAP-Ad-hoc: PAION AG / Key word(s): Research Update PAION REPORTS POSITIVE HEADLINE DATA IN U.S. CLINICAL SAFETY TRIAL OF REMIMAZOLAM IN HIGH-RISK PATIENTS UNDERGOING COLONOSCOPY 26-March-2017 / 23:22 CET/CEST Disclosure of an inside information …